bluebird bio
BLUE
$0.90
Share price
-1.21%
Change (1 day)
-79.44%
Change (1 year)
P/S ratio for bluebird bio (BLUE)
P/S ratio as of May 2024 (TTM): 8.07
According to bluebird bio 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.06685. At the end of 2023 the company had a P/S ratio of 15.0.
P/S ratio history for bluebird bio from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 15.0 | -90.61% |
| 2022 | 159 | |
| 2021 | N/A | -100% |
| 2020 | 11.5 | -89.47% |
| 2019 | 109 | 9.31% |
| 2018 | 99.5 | -59.67% |
| 2017 | 247 | -34.03% |
| 2016 | 374 | 122.22% |
| 2015 | 168 | 44.22% |
| 2014 | 117 | 368.84% |
| 2013 | 24.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 2.48 | -69.26% | 🇫🇷 France |
 Merck MRK | 5.43 | -32.72% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | 0.6403 | -92.06% | 🇺🇸 USA |
 Acceleron Pharma XLRN | N/A | N/A | 🇺🇸 USA |
 GlycoMimetics
GLYC | > 1000 | 129,330.94% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 6.54 | -18.92% | 🇺🇸 USA |